The global health check-up market size was estimated at around USD 48.74 billion in 2022 and it is projected to hit around USD 82 billion by 2032, growing at a CAGR of 5.34% from 2023 to 2032. The health check-up market in the United States was accounted for USD 2.8 billion in 2022.
Key Pointers
Report Scope of the Health Check-up Market
Report Coverage | Details |
Revenue Share of North America in 2022 | 38% |
Revenue Forecast by 2032 | USD 82 billion |
Growth Rate from 2023 to 2032 | CAGR of 5.34% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Companies Covered | Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; SYNLAB International GmbH; OPKO Health, Inc. (BioReference Health; LLC.); Eurofins Scientific; UNILABS; Sonic Healthcare Limited; ARUP Laboratories; Q2 Solutions; Laboratory Corporation of America Holdings; LalPathLabs.com |
The market growth is attributable to the increasing prevalence of chronic diseases, rising investments from government bodies to establish population medical screening initiatives, and the adoption of telemedicine & home-based services. For instance, in May 2023, the Indian Health Ministry launched a medical screening initiative for people with hypertension and diabetes. This initiative will provide standard care to around 75 million people suffering from non-communicable diseases by 2025.
Moreover, the introduction of telemedicine in general healthcare practices fueled the home-based testing market, while the healthcare ecosystem's digital connectivity framework powered the health check-up market during the COVID-19 pandemic. The increasing prevalence of life-threatening diseases is one of the key drivers for the industry. Additionally, non-communicable diseases such as diabetes, hypertension, cancer, and cardiovascular diseases are increasing, which often remain asymptomatic in the early stages. For instance, as per an AMGA article, more than 30% of the U.S. population suffers from prehypertension, increasing the chances of developing high blood pressure. Regular health check-up allows individuals to manage the condition effectively, as only 1 in 4 U.S. adults have their hypertension under control.
Additionally, government bodies are undertaking initiatives to screen the target population for different medical conditions. For instance, the U.S. Preventive Services Task Force (USPSTF) recommends yearly screening for adults aged 18 and older to manage blood pressure risks. Similarly, Middle Eastern economies have initiated medical screening programs to raise awareness of the increasing hypertension prevalence. For instance, in May 2023, the Ministry of Health and Prevention (MoHAP) UAE launched a national campaign for the early detection of hypertension. By 2030, UAE plans to reduce the prevalence of high blood pressure by 30%. Hence, increasing recommendations from government bodies will be key drivers for the global market.
The global market is experiencing innovation driven by the adoption of digital technology in the healthcare ecosystem. In the Europe region, countries are integrating medical services to improve healthcare facilities across multiple countries, which is driving the need for digital technologies. For instance, in June 2022, Nordic countries launched Nordic Interoperability Project (NIP) which aims to enable healthcare service providers in Sweden, Denmark, Norway, Finland, and Iceland to evaluate an integrated digital medical ecosystem focused on self-management and preventive care. Additionally, a proposal from the European Commission in May 2022 plans to create a European Health Data Space, which will harness the medical data of nearly 450 million people, thereby establishing cross-border digital healthcare connectivity. Increasing health monitoring through digital platforms will increase the adoption of general & preventive tests over the forecast period.
The availability of health insurance coverage that includes preventive care benefits encourages individuals to undergo routine check-ups, thereby driving market growth. For instance, as per the U.S. CDC, private health insurance in the U.S. covers around 66% of the insured population. In recent years, there has been a shift in insurance policies to prioritize preventive care. Most insurance providers now include preventive care services, such as health check-ups, vaccinations, and screenings, as part of their coverage at no additional cost. Furthermore, insurance companies require policyholders to undergo medical risk assessments as part of the underwriting process. These assessments typically involve health check-ups and help insurers assess the individual's wellness and determine appropriate coverage and premiums. Hence, underwriting processes and growing awareness of preventive care are anticipated to drive market growth.
Type Insights
The general health check-up segment held the largest share of 37% in 2022. General health check-up provides a comprehensive overview of the individual’s health, helping to identify risk factors and manage the health condition at early stages. Furthermore, healthcare professionals widely recommend general health check-ups as they contribute to reducing disease burdens in the future. Moreover, individuals are focusing on proactively managing their well-being, which will drive the market during the forecast period. Furthermore, insurance companies are providing preventive medical services with no-cost sharing benefits, which will help the market growth. For instance, in May 2023, KFF’s article estimated that 151.6 million U.S. citizens were covered by private insurance with a preventive no-cost sharing policy.
The specialized health check-up segment is expected to show the fastest growth rate during the forecast period. Specialized health check-ups focus on cardiovascular health, cancer screenings, metabolic disorders, or genetic predispositions. Targeted screenings and tests provide individuals with a comprehensive assessment and early detection of condition-specific risks. For instance, as per Cancer Research UK, an estimated 20.1 million people globally develop cancer each year with deaths exceeding 10 million annually. However, as per WHO report, 30%-50% of all cancer cases and deaths are preventable if targeted screening is diligently performed.
Test Type Insights
The blood glucose tests held the largest share of 22% in 2022, which can be attributed to the increasing cases of diabetes across the globe. Blood glucose tests, such as fasting blood sugar (FBS) and oral glucose tolerance tests (OGTT), are important in diagnosing and monitoring diabetes. Additionally, early detection of diabetes allows timely intervention and disease management, which can help prevent or delay complications associated with the disease. For instance, the National Center for Chronic Disease Prevention and Health Promotion estimated that nearly 96 million U.S. adults have prediabetes, while the average prevalence rate of prediabetes has increased by 3% from 2013 to 2020. Hence, the growing prevalence of prediabetes and diabetes is anticipated to provide lucrative growth opportunities to the global players in the global market.
The tumor biomarkers segment is expected to register the fastest growth rate during the forecast period. Tumor biomarker tests identify individuals with a higher risk of developing cancer-based on their biomarker profiles, family history, or other risk factors. In addition, tumor biomarkers provide valuable information on molecular characteristics, helping to create novel treatments. The inclusion of novel tumor biomarker test in preventive and specialized health check-up plans are expected to drive the segment growth during the forecast period.
Application Insights
The cardiovascular diseases segment held the largest market share of 29% in 2022, attributed to increasing disease prevalence, high mortality rates, and advancement in testing products. Cardiovascular diseases are the leading cause of death in the U.S., with conditions such as coronary heart disease (CHD), a major contributor to heart attacks. According to the American Heart Association, nearly 400,000 deaths in the U.S. were directly correlated with CHD. However, medical diagnostic companies are developing novel and highly sensitive CHD tests to reduce disease mortality with an early-stage diagnosis of the disease. For instance, in April 2023, Cardio Diagnostic Holdings Inc. launched a PrecionCHD blood test to detect coronary heart diseases. The platform is built by using the company’s AI and biomarkers such as epigenetic and genetic, which helps in improving the clinical specificity of the CHD test by 75%.
The cancer segment is expected to grow at the fastest rate during the forecast period. The growth is attributed to the increasing prevalence of cancer across the economies, with high mortality rates in significant countries. Additionally, early detection of cancer can result in significant healthcare savings. For instance, as per an article published on MJH Life Sciences in November 2020, early diagnosis and screening of cancer can save around USD 26 billion annually. Additionally, cancer-related deaths can be reduced by 24% if cancer diagnosis is done from stage 1 to stage 3. Thereby, healthcare professionals are guiding at-risk people to undergo medical check-ups throughout the year, which is anticipated to contribute to the segment's growth during the forecast period.
Service Provider Insights
Hospital-based laboratories dominated the market with a share of 59% in 2022. Hospital-based laboratories are equipped with advanced medical equipment and infrastructure for conducting a wide range of diagnostic tests and screenings, thereby providing demand for the segment. Additionally, they have access to state-of-the-art technologies and facilities, which helps drive the revenue for health check-ups. For instance, in March 2023, White Plains Hospital launched a new in-house laboratory powered by innovative technologies, thereby, allowing to facilitate faster diagnosis and treatment for a larger patient pool. In addition, hospital-based laboratories are integrated with hospital services which enables an effective follow-up on health check-ups, curating a strong demand for hospital-based labs.
The standalone laboratories segment is expected to show the fastest growth rate during the forecast period. The high growth rate can be attributed to the ability of standalone labs to offer more competitive pricing structures than hospital-based laboratories. The low-cost structure is due to lower overhead and administrative costs than hospital-based laboratories. Additionally, established healthcare providers are expanding into standalone laboratories to provide service specificity and patient loyalty. For instance, in December 2021, MD Medical Group launched its first standalone medical lab in Moscow to facilitate specific services of “mother and child” diagnostics in the region.
End-use Insights
The individuals segment held the largest market share of 69% in 2022 attributed to the increasing awareness of general & preventive health benefits amongst the general population. Health check-ups are also recommended by healthcare professionals to understand disease prognosis and treatment methodologies. Individual end-users often pay the fee out of pocket or through private insurance. The segment’s growth is attributed to the increasing health consciousness among individuals and the desire for early detection and intervention to maintain well-being.
The enterprise segment of the market is expected to grow at the fastest rate during the forecast period. Enterprises such as multinational corporations, educational institutions, and government bodies offer health check-ups as an employee wellness benefit to assess the medical status of their employees, identify potential medical risks, and offer appropriate interventions. Moreover, individuals often face difficulty undergoing health check-ups owing to time constraints; hence, enterprise-based users provide strong health feasibility to employees. For instance, according to the American Academy of Family Physicians article published in April 2023, nearly half of all American women skipped a preventive health check-up service in the last year due to high out-of-pocket costs and problems in scheduling appointments.
Regional Insights
North America dominated the market with a share of 38% in 2022, it is due to the increasing healthcare coverage across the region. For instance, within the U.S., public and private insurance offers distinct advantages while covering a specific population base, and providing health check-ups across the country. For instance, as per Census Bureau’s report on insurance coverage in the U.S., nearly 35.7% of people held public health insurance coverage in 2021. In addition, the uninsured healthcare rate of U.S. children fell to 5.0% in 2021. Thereby, universal coverage across ages provides growth impetus to the health check-up industry in the region.
The Asia-Pacific region is expected to grow at the fastest rate during the forecast period. The market growth is due to the increasing government initiatives to improve healthcare services owing to an increased incidence of communicable and non-communicable diseases. For instance, in March 2023, the Indian Council of Medical Research (ICMR) informed the Indian government that cancer cases in the country are estimated to rise from 1.46 million in 2022 to 1.57 million in 2025. Moreover, the country has announced a population-based screening initiative for non-communicable diseases such as hypertension, common cancer, and diabetes. Due to the growing medical screening initiatives by governments across the economies, the region is anticipated to provide lucrative growth opportunities to the health check-up industry players.
Health Check-up Market Segmentations:
By Type
By Test Type
By Application
By Service Provider
By End-use
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Health Check-up Market
5.1. COVID-19 Landscape: Health Check-up Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Health Check-up Market, By Type
8.1. Health Check-up Market, by Type, 2023-2032
8.1.1. General Health Check-up
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Preventive Health Check-up
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Specialized Health Check-up
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Routine and Wellness Health Check-up
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Health Check-up Market, By Test Type
9.1. Health Check-up Market, by Test Type, 2023-2032
9.1.1. Blood Glucose Test
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Kidney Function Test
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Bone Profile Test
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Electrolyte Test
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Liver Function Test
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Lipid Profile Test
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Special Biochemistry
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Cardiac Biomarkers
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Hormones & Vitamins
9.1.9.1. Market Revenue and Forecast (2020-2032)
9.1.10. Tumor Markers
9.1.10.1. Market Revenue and Forecast (2020-2032)
9.1.11. Others
9.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Health Check-up Market, By Application
10.1. Health Check-up Market, by Application, 2023-2032
10.1.1. Cardiovascular Diseases
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Metabolic Disorders
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cancer
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Inflammatory Conditions
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Neurological Conditions
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Health Check-up Market, By Service Provider
11.1. Health Check-up Market, by Service Provider, 2023-2032
11.1.1. Hospital-Based Laboratories
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Central Laboratories
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Standalone Laboratories
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Health Check-up Market, By End-use
12.1. Health Check-up Market, by End-use, 2023-2032
12.1.1. Enterprise
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Individuals
12.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Health Check-up Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2020-2032)
13.1.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.1.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.1.5. Market Revenue and Forecast, by End-use (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.1.7. Market Revenue and Forecast, by End-use (2020-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2020-2032)
13.1.8.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.1.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.8.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.1.8.5. Market Revenue and Forecast, by End-use (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2020-2032)
13.2.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.2.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.2.5. Market Revenue and Forecast, by End-use (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.7. Market Revenue and Forecast, by Service Provider (2020-2032)
13.2.8. Market Revenue and Forecast, by End-use (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.10. Market Revenue and Forecast, by Service Provider (2020-2032)
13.2.11. Market Revenue and Forecast, by End-use (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.2.13. Market Revenue and Forecast, by End-use (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.2.15. Market Revenue and Forecast, by End-use (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2020-2032)
13.3.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.3.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.3.5. Market Revenue and Forecast, by End-use (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.3.7. Market Revenue and Forecast, by End-use (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.3.9. Market Revenue and Forecast, by End-use (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-use (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-use (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2020-2032)
13.4.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.4.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.4.5. Market Revenue and Forecast, by End-use (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.4.7. Market Revenue and Forecast, by End-use (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.4.9. Market Revenue and Forecast, by End-use (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-use (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-use (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2020-2032)
13.5.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.5.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.5.5. Market Revenue and Forecast, by End-use (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.5.7. Market Revenue and Forecast, by End-use (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Test Type (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Service Provider (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 14. Company Profiles
14.1. Quest Diagnostics Incorporated
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Laboratory Corporation of America Holdings
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. SYNLAB International GmbH
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. OPKO Health, Inc. (BioReference Health; LLC.)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Eurofins Scientific
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. UNILABS
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sonic Healthcare Limited
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. ARUP Laboratories
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Q2 Solutions
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Laboratory Corporation of America Holdings
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms